Full text can be accessed from: http://www.sciencedirect.com/science/article/pii/S0264410X14017058

Manuel Alexander Haasis1*, Joyce Anne Ceria1, Wantanee Kulpeng2, Yot Teerawattananon2, Marissa Alejandria3 1 National Center for Pharmaceutical Access and Management (NCPAM), Department of Health, Manila, Philippines, 2 Health Intervention and Technology Assessment Program (HITAP), Department of

Kittiphong Thiboonboon1 , Benjarin Santatiwongchai1 ,Varit Chantarastapornchit1 , Waranya Rattanavipapong1 , Yot Teerawattananon1 Abstract Background For more than three decades, the number and influence of economic evaluations of healthcare interventions have been increasing and gaining atte

Siriporn Pooripussarakul1, Arthorn Riewpaiboon1* , David Bishai2, Charung Muangchana3 and Sripen Tantivess4 Abstract Background: There is a need to identify rational criteria and set priorities for vaccines. In Thailand, many licensed vaccines are being considering for introduction into the Ex

Veronika J Wirtz*, Hans V Hogerzeil*, Andrew L Gray*, Maryam Bigdeli, Cornelis P de Joncheere, Margaret A Ewen, Martha Gyansa-Lutterodt, Sun Jing, Vera L Luiza, Regina M Mbindyo, Helene Möller, Corrina Moucheraud, Bernard Pécoul, Lembit Rägo, Arash Rashidian, Dennis Ross-Degnan, Peter N Stephens,

Abstract Background Due to competing health priorities and limited resources, many low-income countries, even those with a high disease burden, are not able to introduce pneumococcal conjugate vaccines. Objective To determine the cost-utility of 10- and 13-valent pneumococcal conjugate vacci

Abstract Background The World Health Organization (WHO) has developed the Total System Effectiveness (TSE) framework to assist national policy-makers in prioritizing vaccines. The pilot was launched in Thailand to explore the potential use of TSE in a country with established governance struct

Abstract Background: Diarrhoea remains one of the top ten causes of under-five child morbidity in Bhutan, and rotavirus is a significant cause of child diarrhoeal hospitalisations. This study sought to determine the health outcomes, cost-effectiveness, and budget and human resource implications o

Beyond vaccine safety, efficacy and procurement lie licensing and delivery — nations must get ready. There are currently more than 40 candidate vaccines for COVID-19 in clinical evaluation, and more than 150 in preclinical development. Creating a safe and effective vaccine is akin to striking bas

Abstract Innovations in vaccine product attributes could play an important role in addressing coverage and equity (C&E) gaps, but there is currently a poor understanding of the full system impact and trade-offs associated with investing in such technologies, both from the perspective of natio